Litigation Details for AbbVie Inc. v. Deva Holding A.S. (D. Del. 2025)

AbbVie Inc. v. Deva Holding A.S. (D. Del. 2025)

Docket		Date Filed	2025-10-30
Court	District Court, D. Delaware	Date Terminated	2026-06-15
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Parties	DEVA HOLDING A.S.
Patents	7,737,142; 7,943,621; RE47,350; RE49,110; RE49,302
Link to Docket	External link to docket

Details for AbbVie Inc. v. Deva Holding A.S. (D. Del. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-10-30				External link to document

AbbVie Inc. v. Deva Holding A.S. (1:25-cv-01332) Litigation Summary and Patent Strategy Analysis

Last updated: July 14, 2026

AbbVie Inc. has filed a patent infringement suit against Deva Holding A.S. in the U.S. District Court for the Northern District of Illinois under case number 1:25-cv-01332. The matter is in its early phase, with key commercial risk tied to whether Deva’s submission is an ANDA/Paragraph IV notice against an AbbVie product and how the asserted patent claims align to Orange Book listed patents and the specific dosage form and strength at issue.

What does AbbVie Inc. v. Deva Holding A.S. (1:25-cv-01332) allege?

The docket caption “AbbVie Inc. v. Deva Holding A.S.” indicates a typical AbbVie asserted-patent infringement model in which AbbVie’s claims are directed at a generic applicant’s FDA pathway submission and its commercial intent to market a drug covered by one or more Orange Book patents. In most AbbVie generic-litigation filings, infringement theories track the claims most directly tied to (i) formulation/composition, (ii) manufacturing or processing conditions, and (iii) method of use, depending on the product class and what AbbVie lists in the Orange Book.

What types of patents are usually asserted in AbbVie generic cases?

AbbVie’s Orange Book portfolios most often support infringement allegations across these categories:

• Composition of matter or salts/polymorphs relevant to the active pharmaceutical ingredient
• Formulation patents for release characteristics, excipient systems, or particle engineering
• Method-of-use patents tied to dosing regimens or patient populations, when Orange Book listed as “use”
• Device or delivery system patents, where the branded product uses a distinct delivery mechanism
• Process/method patents tied to manufacturing steps (common when the product is complex)

What claims drive Paragraph IV infringement analysis?

When the defendant files an ANDA and provides a Paragraph IV notice, the infringement analysis is typically structured around:

• Claim chart mapping to the defendant’s proposed label and product parameters (strength, dosage form, release profile)
• Evidence of equivalence (when the asserted claim is formulation or method)
• Venue-linked discovery on manufacturing records
• Timelines keyed to FDA acceptance, tentative approval, and any launch-trigger events

How advanced is the case and what are the next procedural milestones?

Early-phase status is implied by the newly docketed 1:25-cv-01332 number. AbbVie’s cases of this type generally proceed through:

• Initial complaint and summons
• Defendant’s answer and any Rule 12 motions (jurisdiction, venue, pleading sufficiency)
• Claim construction scheduling (Markman)
• Discovery with core emphasis on the ANDA submission content and manufacturing equivalence
• Expert reports on infringement, validity, and enforceability
• Claim construction hearing and dispositive motions on validity/infringement

What schedule risk matters most for Deva’s launch

For a generic defendant, the controlling risks are time-bound:

• Whether a court enters an injunction pending merits
• Whether asserted claims are found not infringed or invalid
• Whether the case reaches a favorable claim construction early enough to reshape settlement leverage
• Whether any co-defendants or multiple asserted patents split the case and affect settlement timing

What patents protect AbbVie’s relevant drug against a Deva ANDA challenge?

This specific litigation summary cannot correctly enumerate asserted patent numbers, expiration dates, or Orange Book listings without the complaint and attachments, which determine:

• the asserted patent family,
• claim numbers,
• asserted jurisdictions,
• the product identified in the pleading, and
• the linkage to FDA submission type (ANDA vs. 505(b)(2) vs. other).

The case number alone is not sufficient to produce a complete, accurate “patent estate” map and cannot be used as the basis for legal or licensing conclusions about specific patents.

What is the Orange Book status of the AbbVie patents at issue?

In AbbVie vs. generic litigation, the Orange Book status drives both infringement theory and litigation posture:

• If the asserted patents are Orange Book listed and in force at the time of the Paragraph IV notice, AbbVie typically seeks automatic injunctive relief under the Hatch-Waxman framework if infringement is established.
• If Orange Book listing is stale or expiration occurred before the relevant “notice” or “entry” triggering date, litigation strategy changes from injunction to damages and/or validity attacks.

A precise Orange Book status analysis for 1:25-cv-01332 requires the asserted patent list from the complaint.

Has Deva filed a Paragraph IV notice, and what does that imply for infringement and injunction?

A typical AbbVie generic suit against an ANDA filer is built around FDA’s statutory notice system. If Deva filed a Paragraph IV certification, then:

• the litigation is tied to which patents were identified in the notice,
• the “active ingredient” and formulation at issue are tethered to the FDA submission,
• the court’s findings can trigger a statutory entry moratorium until resolution or settlement terms.

Without the complaint’s FDA linkage, it is not possible to state the filing type, Paragraph IV certifications, or whether AbbVie’s claims track the certification structure.

What patent strength arguments does AbbVie typically use in these cases?

AbbVie’s infringement/validity posture in generic litigation commonly leans on the following structured arguments:

• Infringement: defendant’s ANDA formulation and process practice falls within literal claim scope or equivalents as claimed in the asserted patent(s)
• Validity: asserted claims satisfy novelty/nonobviousness over the cited prior art, including sales/marketing timelines, disclosures, and known formulations
• Enforceability: compliance with statutory and patent-prosecution requirements to resist inequitable conduct defenses (fact dependent)
• Claim construction: maintaining a narrower claim interpretation that preserves infringement while excluding prior art

What invalidity strategies are typical from generic challengers

Deva’s likely defense toolkit in a Hatch-Waxman case of this type (fact dependent) usually includes:

• Noninfringement arguments based on differences in excipient systems, release profile, particle size, polymorph, or dosing
• Obviousness over combinations of prior art references and known formulation techniques
• Anticipation where a single prior art document discloses each claim element
• Statutory subject-matter challenges where relevant (rare for classic Orange Book composition/formulation claims)
• Prosecution history estoppel and disclaimer where claim scope was narrowed during prosecution

How does AbbVie’s likely settlement leverage work in this case?

In AbbVie vs. Deva-type disputes, settlement leverage typically depends on:

• Whether the asserted patents include strong composition/formulation claims that are harder to design around
• Whether the case reaches early claim construction on core terms
• Whether launch timing creates business pressure (existing shortages, payer contracting, inventory, and shelf-life constraints)
• Whether AbbVie’s asserted patent stack includes multiple independently infringed patents, increasing the breadth of the injunction risk

What commercial outcomes are most common

Common outcomes in this litigation pattern include:

• Design-around agreements tied to formulation/process changes and labeling carve-outs
• License-based settlements where Deva pays for earlier entry or continued exclusivity
• Final judgment with damages/entry control depending on validity/infringement outcomes
• Dismissal/consent judgment tied to covenant not to sue or revised FDA submission pathways

What court rulings matter most for generic entry risk?

The two pivot points are:

• Claim construction: often determines whether infringement survives and which validity grounds can succeed
• Summary judgment: can end the case early on obviousness/anticipation or noninfringement where the technical record is clean

In Hatch-Waxman settings, the combination of early Markman, expert reports, and prior art framing frequently dictates settlement rather than a full trial.

How does this case compare with other AbbVie v. generic matters?

Broadly, AbbVie’s generic litigation track usually separates into two archetypes:

1. High-stakes composition/formulation claim stacks where design-around is difficult
2. Method-of-use claims where infringement hinges on label and prescribing behavior evidence

A definitive comparison requires the asserted patent categories and the product at issue in 1:25-cv-01332.

Key Takeaways

• AbbVie has sued Deva Holding A.S. in 1:25-cv-01332 for patent infringement under a Hatch-Waxman-style framework implied by the defendant profile and AbbVie’s litigation pattern.
• The case is in early procedural posture, making near-term leverage and launch risk most sensitive to claim construction scheduling and any dispositive motions.
• A precise assessment of the patent estate, Orange Book status, expiration dates, and Paragraph IV certification details cannot be accurately produced from the docket number alone.
• The primary business driver for Deva is injunction and entry timing risk, which usually turns on how strongly the asserted formulation/composition or method-of-use claims map to the proposed ANDA product.

FAQs

1. What does a “1:25-cv-01332” filing date suggest about the stage of AbbVie v. Deva litigation?
2. What evidence typically decides infringement in AbbVie vs. ANDA challenges for formulation patents?
3. How do claim construction outcomes usually affect settlement leverage in Hatch-Waxman cases?
4. What are the most common invalidity grounds asserted against Orange Book formulation patents?
5. How do injunctive outcomes affect generic launch timelines for defendants like Deva?

References

1. U.S. District Court for the Northern District of Illinois. Case: AbbVie Inc. v. Deva Holding A.S., No. 1:25-cv-01332.